Aviir is a technology company.
Aviir has raised $49.0M across 8 funding rounds.
Aviir has raised $49.0M in total across 8 funding rounds.
Aviir has raised $49.0M in total across 8 funding rounds.
Aviir's investors include Aberdare Ventures, Advent Life Sciences, MPM Capital.
Aviir, Inc. was a US-based biotechnology company that developed and commercialized diagnostic laboratory tests focused on cardiometabolic health, particularly for the prevention and management of cardiovascular diseases.[1][2][5] It provided personalized information to physicians through advanced tests employing the latest technologies, targeting hospitals, clinics, and healthcare providers, with operations centered in Irvine, California, and annual revenue around $12.8 million at its peak.[1][4][5] The company addressed critical gaps in cardiovascular risk assessment by offering specialized cardiometabolic tests and services, though it ultimately ceased operations, as noted in employee reviews.[6]
Aviir emerged as a venture-funded biotechnology startup without specific public details on founding year, founders, or early traction in available records, but it established itself in Irvine, California, as a provider of innovative diagnostic solutions.[1][4] The idea likely stemmed from the need for advanced, personalized lab tests in cardiovascular care, evolving into a focus on commercializing technologies for disease prevention and management.[2][5] Pivotal moments included securing venture funding and scaling to a team of about 15 employees, though the company later closed, leaving a positive legacy in workplace culture per former staff.[4][6]
Aviir stood out in the biotech diagnostics space through:
These elements positioned it as a niche player in precision diagnostics, though its small scale (15 employees) limited broader ecosystem impact.[4][6]
Aviir rode the wave of precision medicine and biotech diagnostics trends in the early 2010s, capitalizing on growing demand for personalized cardiovascular risk assessment amid rising chronic disease rates.[1][5] Timing aligned with advances in lab technologies enabling targeted testing, supported by venture funding in a booming health tech sector.[1][2] It contributed modestly to the startup ecosystem by validating cardiometabolic testing models, influencing physician adoption of data-driven prevention, though its closure highlights challenges like market competition and funding pressures in biotech.[6]
With Aviir having shut down, its direct trajectory ended, but its model underscores enduring trends in AI-enhanced diagnostics and personalized cardiology, likely absorbed into larger players or inspiring successors in cardiovascular biotech.[6] Future innovations in this space—driven by AI integration and wearable data—could revive similar ventures, amplifying impact on global heart disease prevention. Aviir's story reminds investors of biotech's high-reward volatility, tying back to its promise as a venture-backed pioneer in life-saving personalization.[1][5]
Aviir has raised $49.0M across 8 funding rounds. Most recently, it raised $10.0M Series B in February 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2013 | $10.0M Series B | Aberdare Ventures, Advent Life Sciences, MPM Capital | |
| Dec 1, 2011 | $10.0M Venture Round | Aberdare Ventures, Advent Life Sciences, MPM Capital | |
| Jun 1, 2011 | $3.0M Venture Round | Aberdare Ventures, Advent Life Sciences, MPM Capital | |
| Jan 1, 2010 | $4.0M Venture Round | Aberdare Ventures, Advent Life Sciences, MPM Capital | |
| Oct 1, 2009 | $1.0M Venture Round | Aberdare Ventures, Advent Life Sciences, MPM Capital | |
| Dec 1, 2008 | $8.0M Venture Round | Aberdare Ventures, Advent Life Sciences, MPM Capital | |
| Mar 1, 2008 | $2.0M Venture Round | Aberdare Ventures, Advent Life Sciences, MPM Capital | |
| Sep 1, 2007 | $11.0M Series B | Aberdare Ventures, Advent Life Sciences, MPM Capital |